KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer

British Journal of Cancer

Volumn 112, Issue 4, 2015, Pages 720-728

  Renaud, S ^a,b   Romain, B ^b,c   Falcoz, P E ^a   Olland, A ^a   Santelmo, N ^a   Brigand, C ^c   Rohr, S ^c   Guenot, D ^b   Massard, G ^a  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

BRAF; colorectal cancer; KRAS; lung; metastases

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HAZARD RATIO; HUMAN; LIVER METASTASIS; LUNG METASTASECTOMY; LUNG METASTASIS; LUNG RESECTION; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS RESECTION; MIDDLE AGED; MOLECULAR GENETICS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; THORACOTOMY; THORAX; THORAX SURGERY; WILD TYPE; ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84923462929     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.499     Document Type: Article

References (41)

1. Adam R, De Haas RJ, Wicherts DA, Vibert E, Salloum C, Azoulay D, Castaing D. (2011). Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery?. Ann Surg 253(2): 349-359
2. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J,Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, De Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA,Wadler S, Malik S, Krtolica K, Urosevic N. (2001). Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85(5): 692-696
3. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. (1998). Kirsten ras mutations in patients with colorectal cancer: the multicenter RASCAL study. J Natl Cancer Inst 90(9): 675-684
4. August DA, Ottow RT, Sugarbaker PH. (1984). Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3(4): 303-324
5. Baron O, Amini M, Duveau D, Despins P, Sagan CA, Michaud JL. (1996). Surgical resection of pulmonary metastases from colorectal carcinoma. Five-year survival and main prognostic factors. Eur J Cardiothorac Surg 10(5): 347-351
6. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, De Castro Carpeno J, Belda-Iniesta C, Barriuso J, Moreno Garcia V, Larrauri J, Lopez R, Casado E, Gonzalez-Baron M, Feliu J. (2009). KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 4(12): e8199
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5): 373-383
8. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. (2005). The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54(9): 1283-1286
9. Diaz Jr LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404): 537-540
10. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374-1403
11. Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. (2013). The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet 206(1-2): 26-31
12. Girard P, Ducreux M, Baldeyrou P, Rougier P, Le Chevalier T, Bougaran J, Lasser P, Gayet B, Ruffie P, Grunenwald D. (1996). Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 14(7): 2047-2053
13. Hamaji M, Cassivi SD, Shen KR, Allen MS, Nichols FC, Deschamps C, Wigle DA. (2012). Is lymph node dissection required in pulmonary metastasectomy for colorectal adenocarcinoma?. Ann Thorac Surg 94(6): 1796-1800
14. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. (2009). A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27(5): 672-680
15. Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE, Yip L. (2013). BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol 20(1): 47-52
16. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. (2012). Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104(3): 228-239
17. Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz Jr. LA, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA. (2013). Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 119(23): 4137-4144
18. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17): 1757-1765
19. Kastrinakis WV, Ramchurren N, Maggard M, Steele Jr G, Summerhayes IC. (1995). K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 130(1): 9-14
20. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8): 786-792
21. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8): 3992-3995
22. McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. (1992). Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 53(5): 780-785
23. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. (1992). Lung resection for colorectal metastases. 10-year results. Arch Surg 127(12): 1403-1406
24. Okumura S, Kondo H, Tsuboi M, Nakayama H, Asamura H, Tsuchiya R, Naruke T. (1996). Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 112(4): 867-874
25. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Kohne CH, Hillebrand T, Daniel PT, Fong Y, Lorenz M. (2001). Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 27(1): 80-87
26. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK. (1989). Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7(10): 1407-1418
27. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, ChuaA, Shivasami A, Cummins MM, Murone C, Tebbutt NC. (2011). Impact ofKRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX Trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 29(19): 2675-2682
28. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. (2009). KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27(35): 5931-5937
29. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. (2010). Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28(3): 466-474
30. Russo A, Migliavacca M, Bazan V, Maturi N, Morello V, Dardanoni G, Modica G, Bazan P, Albanese I, La Farina M, Tomasino RM. (1998). Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. Cell Prolif 31(3-4): 139-153
31. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML. (2005). Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65(14): 6063-6069
32. Sauter ER, Bolton JS, Willis GW, Farr GH, Sardi A. (1990). Improved survival after pulmonary resection of metastatic colorectal carcinoma. J Surg Oncol 43(3): 135-138
33. Schweiger T, Hegedus B, Nikolowsky C, Hegedus Z, Szirtes I, Mair R, Birner P, Dome B, Lang G, Klepetko W, Ankersmit HJ, Hoetzenecker K. (2014). EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective followup study. Ann Surg Oncol 21(3): 946-954
34. Sclafani F, Incarbone M, Rimassa L, Personeni N, Giordano L, Alloisio M, Santoro A. (2013). The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer. J Thorac Cardiovasc Surg 145(1): 97-103
35. Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, Drummond KJ, Thomson BN, Usatoff V, Evans PM, Pick AW, Knight S, Carne PW, Berry R, Polglase A, McMurrick P, Zhao Q, Busam D, Strausberg RL, Domingo E, Tomlinson IP, Midgley R, Kerr D, Sieber OM. (2011). KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17(5): 1122-1130
36. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Borger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID. (2010). Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 46(11): 1997-2009
37. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. (2011). Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20): 4623-4632
38. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. (1988). Genetic alterations during colorectal-tumor development. N Engl J Med 319(9): 525-532
39. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. (2005). Colorectal cancer. Lancet 365(9454): 153-165
40. Zabaleta J, Aguinagalde B, Fuentes MG, Bazterargui N, Izquierdo JM, Hernandez CJ, Enriquez-Navascues JM, Emparanza JI. (2011). Survival after lung metastasectomy for colorectal cancer: importance of previous liver metastasis as a prognostic factor. Eur J Surg Oncol 37(9): 786-790
41. Zanella A, Marchet A, Mainente P, Nitti D, Lise M. (1997). Resection of pulmonary metastases from colorectal carcinoma. Eur J Surg Oncol 23(5): 424-427